Collaboration is key to our success. Explore what we’re saying, what we’re sharing and what we’re thinking.
See available jobs
Mölnlycke is a world leading medical solutions company, with the purpose to advance performance in healthcare across the world.
Highly exuding wounds are challenging to treat. That is why we are providing a wound healing solution that clinicians want to see and that patients can feel.
Read news and updates about our company.
Mölnlycke News
February 2, 2024
Mölnlycke’s science-based targets validated
The Science Based Targets initiative (SBTi) has validated that the greenhouse gas (GHG) emission reduction targets submitted by Mölnlycke Health Care...
January 15, 2024
Mepilex Transfer Ag celebrates 10 years of providing gentle and undisturbed wound care
A decade ago, the antimicrobial foam exudate transfer dressing Mepilex® Transfer Ag was introduced as a new option for HCPs and patients in wound...
October 31, 2023
Cebu Surgical Medical Programme 2023 – a proof of concept for the cleft care centre of excellence
Six Mölnlycke volunteers just came back from the first Surgical Medical Programme in Cebu, the Philippines, where a cleft care centre of excellence is...
October 18, 2023
Mölnlycke® wins prestigious award for making a positive impact on society and addressing global challenges
Mölnlycke ® Health Care has been awarded the 2023 Enlightened Growth Leadership Award by The Frost & Sullivan Institute for commitment to creating a...
October 17, 2023
Swedish healthcare company teams up with Dutch artist to co-create art of hospital waste
Artist Maria Koijck challenged the healthcare industry with art project based on waste from own breast cancer surgery Mölnlycke Health Care responded by...
September 1, 2023
Leslie McDonnell joins Mölnlycke’s Board of Directors
Leslie McDonnell has been elected Member of Mölnlycke AB’s Board of Directors on 1 September 2023.
August 31, 2023
Successful 5-year Eurobond issue for Mölnlycke
Gothenburg, 31 August 2023: Mölnlycke, a world-leading medtech company, has successfully raised EUR 400M in the corporate bond market under its Euro...
May 5, 2023
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two...
March 30, 2023
Mölnlycke publishes its integrated 2022 Annual Report
Mölnlycke’s determination to always put customers and patients first made 2022 another successful year, reaching an organic sales growth of 8.4%. Learn...
Mölnlycke is proud to present My Mölnlycke